Article Abstract

Denosumab will play an important role in patients with solid tumours and bone metastases

Authors: Vera Hirsh


Until recently, bisphosphonates, especially zoledronic acid (ZA),
were considered standard treatment for prevention of skeletal
related events (SREs) in patients with bone metastases. This trial
compared the efficacy and safety of denosumab to ZA in the
patients with advanced cancer (Excluding Breast and Prostate
Cancer) or multiple myeloma (1).